Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin

BJU International

Volumn 103, Issue 6, 2009, Pages 736-739

  Gee, Jason R ^a,b   Jarrard, David F ^a   Bruskewitz, Reginald C ^a   Moon, Timothy D ^a,b   Hedican, Sean P ^a   Leverson, Glen E ^a   Nakada, Stephen Y ^a   Messing, Edward M ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Aspirin; BCG; Bladder cancer; Chemoprevention; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; BCG VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT;

AGED; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER MORTALITY; CANCER RECURRENCE; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEART PROTECTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SMOKING;

ADMINISTRATION, INTRAVESICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; BCG VACCINE; CARCINOMA IN SITU; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 61349169494     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08123.x     Document Type: Article

References (14)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Foresman WH, Messing EM. Bladder cancer: natural history, tumor markers, and early detection strategies. Semin Surg Oncol 1997 13 : 299 306
3. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002 94 : 252 66
4. Castelao JE, Yuan JM, Gago-Dominguez M et al. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000 82 : 1364 9
5. Fortuny J, Kogevinas M, Zens M et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol 2007 7 : 13
6. Mohammed SI, Knapp DW, Bostwick DG et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999 59 : 5647 50
7. Gee J, Lee I-L, Grossman HB, Sabichi AL. Effects of COX-2 overexpression on the immortalized, nontumorigenic urothelial cell line SV-HUC. Urol Oncol 2008 Epub ahead of print
8. Gee J, Lee I-L, Jendiroba D et al. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006 15 : 471 7
9. Sabichi AL, Lippman SM. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin Oncol 2004 31 (Suppl. 7 36 44
10. Grubbs CJ, Lubet RA, Koki AT et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl) -nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000 60 : 5599 602
11. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005 294 : 47 55
12. Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006 107 : 2173 9
13. Herr H. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology 2007 70 : 65 8
14. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000 163 : 1124 9